Editorial & Opinion
Sequential therapy with induction chemotherapy and chemoradiotherapy in pre-irradiated recurrent head and neck squamous cell carcinoma incorporating nab-paclitaxel-a commentary of the phase I trial of AFHX followed by concomitant FHX scheme.
| العنوان: | Sequential therapy with induction chemotherapy and chemoradiotherapy in pre-irradiated recurrent head and neck squamous cell carcinoma incorporating nab-paclitaxel-a commentary of the phase I trial of AFHX followed by concomitant FHX scheme. |
|---|---|
| المؤلفون: | Martinez-Trufero J; Medical Oncology Department, University Hospital Miguel Servet, Zaragoza, Spain., Comin Orce A; Medical Oncology Department, University Hospital Miguel Servet, Zaragoza, Spain., Gomez Mugarza P; Medical Oncology Department, University Hospital Miguel Servet, Zaragoza, Spain., Barriendos Sanz S; Medical Oncology Department, University Hospital Miguel Servet, Zaragoza, Spain., Ortega Izquierdo E; Medical Oncology Department, University Hospital Miguel Servet, Zaragoza, Spain. |
| المصدر: | Translational cancer research [Transl Cancer Res] 2023 Apr 28; Vol. 12 (4), pp. 692-696. Date of Electronic Publication: 2023 Apr 06. |
| نوع المنشور: | Editorial; Comment |
| اللغة: | English |
| بيانات الدورية: | Publisher: Pioneer Bioscience Publishing Company Country of Publication: China NLM ID: 101585958 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2219-6803 (Electronic) Linking ISSN: 2218676X NLM ISO Abbreviation: Transl Cancer Res Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: [Hong Kong] : Pioneer Bioscience Publishing Company, [2012]- |
| مستخلص: | Competing Interests: Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tcr.amegroups.com/article/view/10.21037/tcr-23-131/coif). JMT received payment or honoraria for lectures from Astra-Zeneca, Pharmamar, Merck, Clovis, MSD, GSK, and meeting travel expenses from Pharmamar, MSD, Merck, and served on advisory board of Pharmamar, Boehringer-Ingelheim, Deciphera, Eisai. EOI received Payment or honoraria for lectures from Ipsen, Pharmamar, Merck, Eisai, MSD, GSK, and meeting travel expenses form MSD, Merck, and served on advisory board of Eisai. The other authors have no conflicts of interest to declare. |
| التعليقات: | Comment on: Br J Cancer. 2022 Nov;127(8):1497-1506. (PMID: 35945244) |
| References: | N Engl J Med. 2007 Oct 25;357(17):1695-704. (PMID: 17960012) Clin Transl Oncol. 2021 Aug;23(8):1666-1677. (PMID: 33876416) Oral Oncol. 2021 Apr;115:105173. (PMID: 33548860) Cancer Res Treat. 2016 Jul;48(3):907-16. (PMID: 26582394) Oral Oncol. 2017 Sep;72:26-31. (PMID: 28797458) J Clin Oncol. 2005 Dec 1;23(34):8636-45. (PMID: 16275937) Med Oncol. 2019 Oct 8;36(11):93. (PMID: 31595355) Oral Oncol. 2022 Apr;127:105807. (PMID: 35263677) Oral Oncol. 2018 May;80:40-51. (PMID: 29706187) Oral Oncol. 2018 Sep;84:46-51. (PMID: 30115475) Br J Cancer. 2022 Nov;127(8):1497-1506. (PMID: 35945244) Oral Oncol. 2019 Nov;98:35-47. (PMID: 31536844) Med Oncol. 2021 Mar 8;38(4):35. (PMID: 33683482) Clin Cancer Res. 2002 May;8(5):1038-44. (PMID: 12006516) Radiother Oncol. 2016 Feb;118(2):238-43. (PMID: 26589131) J Control Release. 2013 Sep 28;170(3):365-72. (PMID: 23770008) Head Neck. 2008 Mar;30(3):281-8. (PMID: 17764087) |
| فهرسة مساهمة: | Keywords: Nab-paclitaxel; re-irradiation; recurrent head and neck squamous cell carcinoma; sequential therapy (ST) |
| تواريخ الأحداث: | Date Created: 20230514 Latest Revision: 20230516 |
| رمز التحديث: | 20240628 |
| مُعرف محوري في PubMed: | PMC10174998 |
| DOI: | 10.21037/tcr-23-131 |
| PMID: | 37180677 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 2219-6803 |
|---|---|
| DOI: | 10.21037/tcr-23-131 |